Daurismo is a cancer medicine for treating adults with newly\-diagnosed acute myeloid leukaemia (AML), a cancer of white blood cells. It is used in combination with a low dose of cytarabine (another cancer medicine) when the patient cannot be treated with standard chemotherapy. The active substance in Daurismo is glasdegib. Acute myeloid leukaemia is rare, and Daurismo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 16 October 2017\.
Therapeutic Indication
Daurismo is indicated, in combination with low\-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
Therapeutic Area (MeSH)
ATC Code
L01XX63
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Glasdegib maleate | N/A | Glasdegib maleate |
EMA Name
Daurismo
Medicine Name
Daurismo
Aliases
N/ANo risk management plan link.
